Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 18, 2010

View Archived Issues

HemaQuest begins phase II HQK-1004 trial in EBV-related malignancies

Domain Therapeutics claims new adenosine A2A receptor antagonists

Avalon Pharma discloses new modulators of gene expression

Bristol-Myers Squibb describes new inhibitors of beta-amyloid production

Abbott claims new PARP-1 inhibitors

Rigel Pharmaceuticals discovers new PKC inhibitors

Starpharma begins phase II trial of VivaGel in bacterial vaginosis

Serum PICP level may predict profibrotic state and risk of hypertrophic cardiomyopathy

Beta-amyloid(1-42)/P-tau181P biomarker mixture model detects Alzheimer's disease pathology

Probenecid and cilastatin reduce cardiac fibrosis and myocyte hypertrophy ex vivo

Zoniporide exhibits cardioprotective effect in preclinical study

In vitro repopulation of lung matrix yields bioartificial lungs suitable for in vivo implantation

European Commission grants orphan designation to Vertex's cystic fibrosis candidate

Lilly reports key events of past quarter

BiondVax obtains approval for phase II trial of universal influenza vaccine

Cryo-Cell and Monash University enter into autoimmune disease collaboration

Mesoblast provides update on phase III bone marrow transplant program

Palatin Technologies reports phase I safety data on bremelanotide in ED

Medtronic complements bone healing portfolio with Osteotech acquisition

European Commission grants midostaurin orphan drug status in mastocytosis

Lilly decides to halt development of semagacestat for AD

BioMarin to evaluate neuropsychiatric effects of Kuvan in phase IIIb trial in PKU

Depomed to begin phase III trial of Serada for menopausal hot flashes

Oxford BioMedica and Emergent announce licensing agreement

Phylogica and MedImmune join to identify antimicrobial peptides

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Fauci’s silence may put him in contempt of Congress
BioWorld
After repeatedly invoking the Fifth Amendment to every question asked during the July 29 hearing of the U.S. Senate Homeland Security Committee, Anthony Fauci,...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...